← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Nichols Weston
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001746376
Purchase history
- Companies traded
- 5
- Purchases · 12M
- 6
- Purchases · 24M
- 14
- Average purchase
- $1.6M
- Median purchase
- $334.8K
- Gross purchase value
- $22.0M
Companies: Cullinan Therapeutics, Inc. | Korro Bio, Inc. | Neuphoria Therapeutics Inc. | Passage BIO, Inc. | TScan Therapeutics, Inc.
14 SEC accession(s) · 14 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-13 | Korro Bio, Inc. | KRRO | 10% Owner | $78.8K | Open filing |
| 2026-06-29 | Passage BIO, Inc. | PASG | 10% Owner | $206.2K | Open filing |
| 2025-12-23 | TScan Therapeutics, Inc. | TCRX | 10% Owner | $145.6K | Open filing |
| 2025-10-30 | Cullinan Therapeutics, Inc. | CGEM | 10% Owner | $1.4M | Open filing |
| 2025-10-23 | Neuphoria Therapeutics Inc. | NEUP | 10% Owner | $3.3M | Open filing |
| 2025-10-21 | Cullinan Therapeutics, Inc. | CGEM | 10% Owner | $2.1M | Open filing |
| 2025-10-10 | Cullinan Therapeutics, Inc. | CGEM | 10% Owner | $9.8M | Open filing |
| 2025-09-15 | Passage BIO, Inc. | PASG | 10% Owner | $223.7K | Open filing |
| 2025-07-24 | Passage BIO, Inc. | PASG | 10% Owner | $733.7K | Open filing |
| 2025-05-21 | TScan Therapeutics, Inc. | TCRX | 10% Owner | $3.1M | Open filing |
| 2024-12-31 | Passage BIO, Inc. | PASG | 10% Owner | $242.9K | Open filing |
| 2024-12-16 | TScan Therapeutics, Inc. | TCRX | 10% Owner | $385.7K | Open filing |
| 2024-11-27 | Passage BIO, Inc. | PASG | 10% Owner | $283.8K | Open filing |
| 2024-11-19 | TScan Therapeutics, Inc. | TCRX | 10% Owner | $4.1K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 2/11
- Large purchase ≥ $100k
- 12/14
- Cluster buying · 15D
- 14/14
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.